We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · May 25, 2021

Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic-Naïve Crohn's Disease

Clinical Gastroenterology and Hepatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Gastroenterology and Hepatology
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease
Clin. Gastroenterol. Hepatol. 2021 Apr 07;[EPub Ahead of Print], N Narula, ECL Wong, PS Dulai, NK Sengupta, JK Marshall, JF Colombel, W Reinisch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading